Renaissance Capital logo

ARMO News

A Novel Idea: Biotechs with Innovative Therapies Outperform

ARMO BioSciences logo

Biotech IPOs offer investors a shot at exceptional returns but are often tricky for non-biochemists, which means most investors, to decipher. So we reviewed 2018’s biotech, asking a basic question: are they developing innovative approaches to disease ...read more

Biotechs take the podium with the year's 3 best IPOs

ARMO BioSciences logo

Biotechs hold gold, silver and bronze in the 2018 IPO market. Cancer immunotherapy devloper ARMO BioSciences (ARMO) is by far the year's best-performing IPO, up 200% from its offer price. Rounding out the podium is chronic itch biotech Menlo Therapeutics ...read more

US IPO Week Ahead: Look for a wave of filings in a quiet holiday week with 2 IPOs

AJAX

Two small deals are on the calendar for the holiday week ahead, including single-asset Reg A+ IPO Aspen REIT and blank check company Crescent Funding. We expect IPO filing activity to pick up as we move through the annual mid-February lull...read more